

Niccola Funel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4802846/publications.pdf>

Version: 2024-02-01

89
papers

4,763
citations

109137

35
h-index

98622

67
g-index

91
all docs

91
docs citations

91
times ranked

7968
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. <i>Cancer Research</i> , 2010, 70, 4528-4538.	0.4	409
2	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	0.8	402
3	Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. <i>Cancer Research</i> , 2006, 66, 3928-3935.	0.4	307
4	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	9.4	294
5	Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer. <i>PLoS ONE</i> , 2010, 5, e10630.	1.1	261
6	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015, 47, 911-916.	9.4	224
7	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	5.8	188
8	MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. <i>Gastroenterology</i> , 2014, 146, 268-277.e18.	0.6	141
9	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. <i>Digestive and Liver Disease</i> , 2014, 46, 479-493.	0.4	108
10	TGF- β 2 induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , 2018, 9, 1845.	5.8	101
11	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 1389-1404.	1.3	94
12	Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1735-1746.	1.9	84
13	Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma. <i>Cancer Research</i> , 2013, 73, 6745-6756.	0.4	79
14	Dextran-Catechin Conjugate: A Potential Treatment Against the Pancreatic Ductal Adenocarcinoma. <i>Pharmaceutical Research</i> , 2012, 29, 2601-2614.	1.7	78
15	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6987.	1.4	68
16	High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer. <i>PLoS ONE</i> , 2012, 7, e49145.	1.1	67
17	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. <i>Scientific Reports</i> , 2017, 7, 44686.	1.6	66
18	Role of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt346.	3.0	65

#	ARTICLE	IF	CITATIONS
19	Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 9.	6.9	65
20	The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2020, 60, 238-248.	4.3	65
21	Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. <i>Current Pharmaceutical Design</i> , 2013, 19, 940-950.	0.9	61
22	miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014, 33, 384-393.	0.4	58
23	<sc><i>TERT</i></sc> gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015, 137, 2175-2183.	2.3	57
24	Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. <i>Cancers</i> , 2019, 11, 638.	1.7	57
25	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. <i>Lancet, The</i> , 2015, 385, S37.	6.3	54
26	Robotic pancreatoduodenectomy with vascular resection. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 1111-1122.	0.8	52
27	Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. <i>European Radiology</i> , 2015, 25, 751-759.	2.3	51
28	Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/ β -catenin signalling in pancreatic adenocarcinoma. <i>Oncotarget</i> , 2014, 5, 5335-5349.	0.8	50
29	Imidazo[2,1-b][1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2020, 189, 112088.	2.6	49
30	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 1137-1147.	2.1	47
31	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. <i>Pharmacogenomics</i> , 2011, 12, 1641-1652.	0.6	45
32	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. <i>Digestive and Liver Disease</i> , 2013, 45, 95-99.	0.4	45
33	Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. <i>Biomatter</i> , 2014, 4, e955386.	2.6	42
34	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019, 39, 215-225.	2.7	41
35	Vascular Dysfunction in a Mouse Model of Rett Syndrome and Effects of Curcumin Treatment. <i>PLoS ONE</i> , 2013, 8, e64863.	1.1	41
36	3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Molecules</i> , 2020, 25, 329.	1.7	39

#	ARTICLE	IF	CITATIONS
37	A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 234-242.	1.3	36
38	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. <i>International Journal of Cancer</i> , 2019, 144, 1275-1283.	2.3	36
39	A Model of a Zebrafish Avatar for Co-Clinical Trials. <i>Cancers</i> , 2020, 12, 677.	1.7	36
40	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. <i>JCI Insight</i> , 2020, 5, .	2.3	36
41	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984123.	1.4	35
42	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. <i>Laboratory Investigation</i> , 2008, 88, 773-784.	1.7	34
43	AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e108057.	1.1	34
44	Magnetic carbon nanotubes: a new tool for shepherding mesenchymal stem cells by magnetic fields. <i>Nanomedicine</i> , 2011, 6, 43-54.	1.7	32
45	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. <i>British Journal of Cancer</i> , 2020, 123, 644-656.	2.9	29
46	Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 695-701.	1.5	23
47	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. <i>Pharmacogenomics</i> , 2019, 20, 49-68.	0.6	23
48	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. <i>World Journal of Gastroenterology</i> , 2020, 26, 2792-2809.	1.4	23
49	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy. <i>Clinical Epigenetics</i> , 2015, 7, 129.	1.8	22
50	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1081-1090.	1.3	22
51	Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. <i>Current Pharmaceutical Design</i> , 2013, 19, 940-50.	0.9	22
52	Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 524-533.	3.2	21
53	Ukrain Affects Pancreas Cancer Cell Phenotype in vitro by Targeting MMP-9 and Intra-/Extracellular SPARC Expression. <i>Pancreatology</i> , 2010, 10, 545-552.	0.5	19
54	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. <i>Oncotarget</i> , 2016, 7, 28556-28569.	0.8	19

#	ARTICLE	IF	CITATIONS
55	Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells. <i>Current Drug Targets</i> , 2014, 15, 1331-1340.	1.0	19
56	Mutational Profiling of Kinases in Human Tumours of Pancreatic Origin Identifies Candidate Cancer Genes in Ductal and Ampulla of Vater Carcinomas. <i>PLoS ONE</i> , 2010, 5, e12653.	1.1	16
57	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. <i>Carcinogenesis</i> , 2018, 39, 360-367.	1.3	16
58	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. <i>Cancers</i> , 2019, 11, 1181.	1.7	16
59	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2016, 6, 39565.	1.6	15
60	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. <i>Scientific Reports</i> , 2017, 7, 43812.	1.6	15
61	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. <i>Carcinogenesis</i> , 2016, 37, 957-964.	1.3	14
62	Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells. <i>PLoS ONE</i> , 2018, 13, e0197493.	1.1	14
63	Loss of Heterozygosity Status of D9S105 Marker Is Associated with Downregulation of KrÄ¼ppel-Like Factor 4 Expression in Pancreatic Ductal Adenocarcinoma and Pancreatic Intraepithelial Lesions. <i>Pancreatology</i> , 2011, 11, 30-42.	0.5	12
64	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. <i>Biochemical Pharmacology</i> , 2019, 166, 128-138.	2.0	12
65	5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16437-16450.	0.8	12
66	Silver Nanoparticle-Coated Polyhydroxyalkanoate Based Electrospun Fibers for Wound Dressing Applications. <i>Materials</i> , 2021, 14, 4907.	1.3	11
67	Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. <i>Journal of Nephrology</i> , 2011, 24, 381-385.	0.9	11
68	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. <i>Pharmacogenomics</i> , 2014, 15, 609-618.	0.6	10
69	Evaluation of vascular infiltration in resected patients for pancreatic cancer: comparison among multidetector CT, intraoperative findings and histopathology. <i>Abdominal Imaging</i> , 2007, 32, 737-742.	2.0	9
70	Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report. <i>BMC Surgery</i> , 2020, 20, 331.	0.6	9
71	Triticum vulgare Extract Modulates Protein-Kinase B and Matrix Metalloproteinases 9 Protein Expression in BV-2 Cells: Bioactivity on Inflammatory Pathway Associated with Molecular Mechanism Wound Healing. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	1.4	9
72	Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice. <i>European Journal of Pharmacology</i> , 2014, 729, 37-44.	1.7	8

#	ARTICLE	IF	CITATIONS
73	The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors?. <i>Epigenomics</i> , 2015, 7, 333-335.	1.0	8
74	Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. <i>Anticancer Research</i> , 2019, 39, 3609-3614.	0.5	8
75	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. <i>Cancers</i> , 2021, 13, 4131.	1.7	8
76	Prognostic impact of conservative surgery for pancreatic IPMNs. <i>Surgical Oncology</i> , 2021, 38, 101582.	0.8	7
77	Multidetector CT in the evaluation of retroperitoneal fat tissue infiltration in ductal adenocarcinoma of the pancreatic head: correlation with histopathological findings. <i>Abdominal Imaging</i> , 2010, 35, 465-470.	2.0	6
78	The occurrence of prion protein in surgically resected pancreatic adenocarcinoma. <i>Pancreatology</i> , 2020, 20, 1218-1225.	0.5	6
79	Myoclonus epilepsy, retinitis pigmentosa, leukoencephalopathy and cerebral calcifications associated with a novel m.5513G>A mutation in the MT-TW gene. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 158-162.	1.0	5
80	The odd case of a small and mucinous-like acinar cell cystoadenocarcinoma of the pancreas. <i>Pancreatology</i> , 2012, 12, 421-422.	0.5	4
81	Expression of SP7, RUNX1, DLX5, and CTNNB1 in Human Mesenchymal Stem Cells Cultured on Xenogeneic Bone Substitute as Compared With Machined Titanium. <i>Implant Dentistry</i> , 2014, Publish Ahead of Print, 407-15.	1.7	4
82	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2342-2345.	1.1	4
83	Robotic-assisted versus open left pancreatectomy for cystic tumours: A single-centre experience. <i>Journal of Minimal Access Surgery</i> , 2020, 16, 66.	0.4	4
84	Pancreatic Cancer. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-2.	0.7	2
85	Pancreatoduodenectomy without Vascular Resection in Patients with Primary Resectable Adenocarcinoma and Unilateral Venous Contact: A Matched Case Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-8.	0.7	2
86	Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 7324-7339.	1.4	2
87	Liquid biopsies to optimize therapeutic efficacy in unresponsive lung cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 761-763.	1.5	1
88	Advances in Primary Cell Culture of Pancreatic Cancer. , 2014, , 11-38.		0
89	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy"Letter. <i>Clinical Cancer Research</i> , 2016, 22, 2594-2594.	3.2	0